Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
Open Access
- 30 December 2020
- journal article
- research article
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 16 (6), 1017-1023
- https://doi.org/10.20996/1819-6446-2020-11-12
Abstract
Dual antiplatelet therapy is the most important step in acute coronary syndrome (ACS) treatment. The new generation of inhibitors of P2Y12 platelet receptors (prasugrel and ticagrelor) provide more pronounced platelet inhibition than clopidogrel. The drugs differ in pharmacodynamics and platelet reactivity tests due to different mechanisms of binding to P2Y12 receptors. The antiplatelet effect of prasugrel and ticagrelor provides clinical benefit and better prognosis in patients with various forms of ACS. In patients with ST-segment elevation ACS prasugrel and ticagrelor are preferred over clopi-dogrel due to their higher efficacy and better clinical outcomes, and currently have preferential positions in guidelines compared to clopidogrel. The comparison of prasugrel versus ticagrelor (ISAR-REACT 5 trial) demonstrated superiority of prasugrel over ticagrelor in patients with ST-segment elevation ACS, for whom an invasive evaluation is planned and in early invasive treatment non-ST-segment elevation ACS. The choice of a drug for dual antiplatelet therapy in various clinical situations remains controversial. The latest ESC guidelines on non-ST elevation ACS (2020) [1] demonstrate the possible preference for prasugrel in patients with ACS without ST-segment elevation undergoing percutaneous coronary intervention. Current article demonstrates the results of recent clinical studies and the real clinical data regarding antiplatelet therapy in patients with coronary interventions. The indications for the use of P2Y12 platelet inhibitors in certain groups of patients are outlined. Treatment selection of the most effective and safe drugs in patients with ACS is highlighted according to the updated European guidelines.Keywords
This publication has 29 references indexed in Scilit:
- Novel antiplatelet agents in acute coronary syndromeNature Reviews Cardiology, 2014
- Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary SyndromesThe New England Journal of Medicine, 2013
- Antiplatelet agents for the treatment and prevention of atherothrombosisEuropean Heart Journal, 2011
- Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trialThe Lancet, 2010
- Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery DiseaseJournal of the American College of Cardiology, 2009
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesThe New England Journal of Medicine, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesThe New England Journal of Medicine, 2007
- Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometryRapid Communications in Mass Spectrometry, 2006
- COMMIT/CCS-2 studiesThe Lancet, 2006
- Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment ElevationThe New England Journal of Medicine, 2005